ARCA biopharma
8001 Arista Place
Suite 200
Broomfield
Colorado
80021
United States
Tel: 720-940-2100
Fax: 720-208-9261
Website: http://www.arcabiopharma.com/
145 articles with ARCA biopharma
-
Christopher Graybill Joins ARCA as Vice President, Clinical Development
5/5/2021
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.
-
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update
3/18/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2020 financial results and provided a corporate update.
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
12/9/2020
ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT
-
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
11/23/2020
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not
-
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
11/2/2020
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID 19 anticipated in fourth quarter Topline data from trial anticipated Q2 2021
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.
-
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19
8/12/2020
ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as September 2020
-
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
8/5/2020
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the second quarter of 2020 and provided a corporate update.
-
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
6/3/2020
ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the closing of its previously announced registered direct offering with certain institutional and accredited investors of 348,000 shares of ARCA’s common stock, at a purchase price of $9.00 per share, and pre-funded warrants to purchase 3
-
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
6/1/2020
ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that it has entered into a definitive securities purchase agreement with certain institutional and accredited investors to purchase, in a registered direct offering, 348,000 shares of ARCA’s common stock, at a purchase price of $9.00 per
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
-
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
5/28/2020
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy , a condition characterized by abnormal blood clotting in patients with COVID-19 Previous safety data in more than 700 patients through Phase 2 may enable more rapid development ARCA anticipates filing an IND in the third quarter of 2020 and initiating late-stage clinical testing in the second half of this year Prior rNAPc2 results treating Ebola and Marburg viral infections in non-huma
-
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
5/7/2020
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that clinical data evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF) in patients with heart failure (HF)
-
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
5/6/2020
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results for the first quarter of 2020 and provided a corporate update.
-
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
2/18/2020
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, reported financial results for the year ended December 31, 2019 and provided a corporate update.
-
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
11/6/2019
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, reported financial results for the quarter ended September 30, 2019 and provided a corporate update.
-
ARCA BIOPHARMA ANNOUNCES FDA AGREEMENT FOR A SINGLE PHASE 3 CLINICAL TRIAL TO SUPPORT APPROVAL FOR THE FIRST GENETICALLY-TARGETED CARDIOVASCULAR DRUG
2/20/2019
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 clinical trial, PRECISION-AF, to assess the safety and efficacy of Gencaro